Results 1 to 10 of about 17,313 (143)

Neovascular Glaucoma

open access: yesOphthalmology
Neovascular glaucoma is an aggressive form of secondary angle-closure glaucoma that can potentially lead to blindness. It is characterized by neovascularization of the iris and the drainage angle. The proliferation of fibrovascular tissue within the drainage angle leads to the formation of peripheral anterior synechiae and an increase in intraocular ...
Mishra C, Meyer JJ.
europepmc   +5 more sources

Neovascular Glaucoma [PDF]

open access: yesDelhi Journal of Ophthalmology, 2015
Neovascular glaucoma (NVG) is a secondary ocular pathological condition resulting from a myriad of ocular and systemic conditions with retinal ischemia as a mediator in over 95% of cases. NVG is caused by the growth of a fibrovascular membrane secondary to a local angiogenic stimulus over the trabecular meshwork obstructing aqueous outflow.
Shane J, Havens, Vikas, Gulati
  +8 more sources

Comparison of Outcomes between Endoscopic and Transcleral Cyclophotocoagulation. [PDF]

open access: yes, 2017
Importance: Traditionally cyclophotocoagulation has been reserved as a treatment of last resort for eyes with advanced stage glaucoma, but increasingly it is offered to eyes with less severe disease.
Beardsley, Robert   +7 more
core   +3 more sources

Intraluminal Deposits Found in Glaucoma Tube Shunts Via Anterior Segment Ocular Coherence Tomography [PDF]

open access: yes, 2018
PURPOSE: To describe and characterize a novel observation of intraluminal deposits of glaucoma tube shunts (TS) using spectral domain (SD) ocular coherence topography (OCT).
Alvarado, Jorge A.   +2 more
core   +1 more source

Neovascular glaucoma [PDF]

open access: yesProgress in Retinal and Eye Research, 2007
Neovascular glaucoma (NVG) is a severely blinding, intractable disease. The objective of this review is to provide detailed information on its basic and clinical aspects, to enable us to manage it logically. Therefore, its causes, pathogenesis and pathology, methods of early diagnosis and management are discussed.
openaire   +2 more sources

Proton beam radiotherapy in the management of uveal melanoma: clinical experience in Scotland [PDF]

open access: yes, 2008
<p>Aim: To evaluate proton-beam radiotherapy (PBRT) in the management of uveal melanoma in Scotland.</p> <p>Methods: A retrospective review was undertaken on all patients receiving PBRT for uveal melanoma (1994–2005).
Aziz, S.   +4 more
core   +3 more sources

Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma [PDF]

open access: yes, 2011
Purpose: To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). Methods: Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (> 21 mm Hg)
Haritoglou, Christos   +3 more
core   +1 more source

Neovascular Glaucoma

open access: yesKerala Journal of Ophthalmology, 2018
Neovascular glaucoma (NVG) is an intractable secondary glaucoma characterized by the growth of new vessels accompanied by a fibrovascular membrane over the iris and iridocorneal angle. Majority of the cases of NVG are associated with ischemia and hypoxia of retina.
Tanuj Dada, Talvir Sidhu
  +6 more sources

Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing [PDF]

open access: yes, 2011
Background/aims: With the increased efficacy of current therapy for wet age-related macular degeneration (AMD), better ways to detect wet AMD are needed.
Bababeygy, Simon R.   +5 more
core   +1 more source

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

open access: yes, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy